SEC Filings
Vaxcyte Closes $575 Million Of 1.50% Convertible Notes And A Stock Sale Priced At $64.00
Both over-allotment options were exercised in full, and the notes convert at about $89.60 a share, the company's 8-K says.
PCVX
Vaxcyte (PCVX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Vaxcyte Prices Stock Sale At $64.00 Per Share, With A $500 Million Convertible Deal Alongside
Shares priced 4.0% below the last sale, and net proceeds from both deals are earmarked for VAX-31 trials, manufacturing and a U.S. launch.
SEC Filings
Vaxcyte's 31-Valent Vaccine Hits Every Primary Goal, But Two Serotypes Miss Stricter Bar Against Capvaxive
VAX-31 cleared 17 of 19 shared serotypes against Capvaxive at the tougher threshold; a biologics license filing is planned for the first half of 2028.